NZ582459A - Antimicrobial peptide, compositions, and methods of use - Google Patents
Antimicrobial peptide, compositions, and methods of useInfo
- Publication number
- NZ582459A NZ582459A NZ582459A NZ58245908A NZ582459A NZ 582459 A NZ582459 A NZ 582459A NZ 582459 A NZ582459 A NZ 582459A NZ 58245908 A NZ58245908 A NZ 58245908A NZ 582459 A NZ582459 A NZ 582459A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- composition according
- arg
- kit
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95205907P | 2007-07-26 | 2007-07-26 | |
PCT/US2008/071350 WO2009015385A1 (en) | 2007-07-26 | 2008-07-28 | Antimicrobial peptide, compositions , and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ582459A true NZ582459A (en) | 2012-05-25 |
Family
ID=40281862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ582459A NZ582459A (en) | 2007-07-26 | 2008-07-28 | Antimicrobial peptide, compositions, and methods of use |
Country Status (25)
Country | Link |
---|---|
US (1) | US8623811B2 (pt) |
EP (3) | EP2178549B1 (pt) |
JP (5) | JP5401457B2 (pt) |
KR (4) | KR101722038B1 (pt) |
CN (2) | CN102872447B (pt) |
AU (1) | AU2008278593B2 (pt) |
BR (3) | BR122019000266B1 (pt) |
CA (1) | CA2694046C (pt) |
CO (1) | CO6260098A2 (pt) |
CR (1) | CR11239A (pt) |
CY (2) | CY1118503T1 (pt) |
DK (2) | DK3120862T3 (pt) |
ES (2) | ES2805225T3 (pt) |
HK (1) | HK1180237A1 (pt) |
HR (1) | HRP20161722T1 (pt) |
HU (1) | HUE031136T2 (pt) |
IL (3) | IL203173A (pt) |
LT (1) | LT2178549T (pt) |
MX (1) | MX2010000916A (pt) |
NZ (1) | NZ582459A (pt) |
PL (1) | PL2178549T3 (pt) |
PT (2) | PT2178549T (pt) |
SG (1) | SG188128A1 (pt) |
SI (1) | SI2178549T1 (pt) |
WO (1) | WO2009015385A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007340158A1 (en) * | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Transport molecules using reverse sequence HIV-TAT polypeptides |
EP2178549B1 (en) * | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
CA2715033C (en) | 2008-03-14 | 2014-11-25 | Allergan, Inc. | Immuno-based botulinum toxin serotype a activity assays |
DK3332805T3 (da) * | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
CA2757449A1 (en) * | 2009-04-01 | 2010-10-07 | Revance Therapeutics, Inc. | Methods and compositions for treating skin conditions associated with vascular hyper-reactivity |
CA2765171C (en) | 2009-06-10 | 2018-10-02 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
BRPI1015938A2 (pt) * | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
US10022083B2 (en) | 2011-06-02 | 2018-07-17 | Abdulmohsen E. A. H. Al-Terki | Multiple oral and nasal surgical procedures method and kit |
US8387798B1 (en) | 2012-04-27 | 2013-03-05 | Abdulmohsen E. A. H. Al-Terki | Mutiple oral and nasal surgical procedures method and kit |
FR2997304B1 (fr) | 2012-10-26 | 2017-07-07 | Isp Investments Inc | Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens |
US20140120077A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11446236B2 (en) | 2015-08-05 | 2022-09-20 | Cmpd Licensing, Llc | Topical antimicrobial compositions and methods of formulating the same |
US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
JP2018534247A (ja) | 2015-09-17 | 2018-11-22 | コントラフェクト コーポレイション | 肺サーファクタントによって阻害される抗生物質の肺サーファクタントの存在下における抗細菌活性を回復/増加させるための溶解素の使用 |
US10105381B2 (en) * | 2016-05-23 | 2018-10-23 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
US10144767B2 (en) * | 2016-08-18 | 2018-12-04 | Board Of Regents Of The University Of Nebraska | Anti-microbial peptides and coatings |
AU2017360346B2 (en) * | 2016-11-21 | 2023-11-23 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
US20210162026A1 (en) | 2017-08-28 | 2021-06-03 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
CN107556374B (zh) * | 2017-08-30 | 2020-02-07 | 四川大学 | 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用 |
CN107353334B (zh) * | 2017-08-30 | 2020-02-07 | 四川大学 | 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用 |
JP7266202B2 (ja) * | 2018-02-19 | 2023-04-28 | 株式会社ファンケル | 化粧料及び抗炎症剤 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
JPH08501060A (ja) * | 1992-04-23 | 1996-02-06 | アレリックス バイオファーマスーティカルス インコーポレーテッド | ヘルペスウィルス感染症の治療 |
DE656950T1 (de) | 1992-08-21 | 1996-03-14 | Biogen Inc | Tat-derivate transport polypeptide. |
WO1995011038A1 (en) | 1993-10-22 | 1995-04-27 | Allelix Biopharmaceuticals Inc. | Treatment of cytomegalovirus infection |
DE69435270D1 (de) | 1993-12-28 | 2010-04-01 | Allergan Inc | Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln |
US6232295B1 (en) | 1994-10-12 | 2001-05-15 | Jon Faiz Kayyem | Cell-specific contrast agent and gene delivery vehicles |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
ES2316154T3 (es) | 1995-08-23 | 2009-04-01 | University Of British Columbia | Peptidos cationicos antimicrobianos y procedimientos de seleccion de los mismos. |
US6043218A (en) * | 1996-10-22 | 2000-03-28 | Medical University Of South Carolina | Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
US6221355B1 (en) | 1997-12-10 | 2001-04-24 | Washington University | Anti-pathogen system and methods of use thereof |
JP2002508187A (ja) | 1997-12-12 | 2002-03-19 | オニックス ファーマシューティカルズ,インコーポレイティド | P53+新生細胞の選択的殺死及び診断 |
CN1324246A (zh) | 1998-10-27 | 2001-11-28 | 梅约医学教育与研究基金会 | 增加伤口愈合的方法 |
EP1137664A2 (en) | 1998-12-10 | 2001-10-04 | Washington University | Protein transduction system and methods of use thereof |
EP1140021B1 (en) | 1998-12-23 | 2004-08-04 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
US7056656B1 (en) | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
US20030236214A1 (en) | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
US7008924B1 (en) | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6844324B1 (en) | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US6670322B2 (en) | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
ES2617692T3 (es) | 2000-07-21 | 2017-06-19 | Revance Therapeutics, Inc. | Sistemas de transporte de agentes biológicos de múltiples componentes |
US20030215412A1 (en) | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US20040220100A1 (en) | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
AU2002306500C1 (en) | 2001-02-16 | 2006-09-28 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
EP1401281A4 (en) * | 2001-05-09 | 2004-12-29 | Univ Yale | TOLL / INTERLEUKIN-1 RECEPTOR ADAPTER PROTEIN (TIRAP) |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
EP1461084A2 (en) | 2001-12-11 | 2004-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Guanidinium transport reagents and conjugates |
AU2003216389A1 (en) | 2002-02-21 | 2003-09-09 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
JP4154218B2 (ja) * | 2002-11-27 | 2008-09-24 | 寛紀 高麗 | 新規抗菌性ポリペプチドとその利用 |
CA2508273A1 (en) * | 2002-12-19 | 2004-07-08 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
IL153557A0 (en) * | 2002-12-19 | 2003-07-06 | Yitzchak Hillman | Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases |
PL378571A1 (pl) * | 2003-02-01 | 2006-05-02 | Neuralab Limited | Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß |
US7482016B2 (en) | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
CN1901933A (zh) * | 2003-09-12 | 2007-01-24 | 英属哥伦比亚大学 | 用阳离子肽刺激先天免疫的方法 |
JP2005120050A (ja) * | 2003-10-20 | 2005-05-12 | Toagosei Co Ltd | 新規抗菌性ペプチドとその利用 |
CA3031270A1 (en) | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
EP1729821B1 (en) | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
EP1778720B1 (en) * | 2004-08-18 | 2010-09-01 | Novabiotics Limited | Antimicrobial peptides comprising an arginine- and/or lysine-containing motif |
EP1656951A1 (en) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
WO2006050611A1 (en) | 2004-11-12 | 2006-05-18 | The University Of British Columbia | Antimicrobial peptides |
EP1661912A1 (en) | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
JP4730584B2 (ja) * | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
JP2006238751A (ja) * | 2005-03-02 | 2006-09-14 | Toagosei Co Ltd | ベロ毒素結合性を有する抗菌ペプチド及びその利用 |
EP1861112A4 (en) | 2005-03-03 | 2009-07-22 | Revance Therapeutics Inc | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS |
NZ560799A (en) | 2005-03-03 | 2009-10-30 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
US8580317B2 (en) | 2005-03-30 | 2013-11-12 | Revance Therapeutics, Inc. | Compositions and methods for treating acne |
CN101355962A (zh) | 2005-11-17 | 2009-01-28 | 雷文斯治疗公司 | 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法 |
AU2007340162B2 (en) | 2006-12-29 | 2013-08-01 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
AU2007340158A1 (en) | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Transport molecules using reverse sequence HIV-TAT polypeptides |
EP2178549B1 (en) * | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
DK3332805T3 (da) | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
-
2008
- 2008-07-28 EP EP08826608.5A patent/EP2178549B1/en active Active
- 2008-07-28 EP EP20166266.5A patent/EP3741380A1/en active Pending
- 2008-07-28 BR BR122019000266-5A patent/BR122019000266B1/pt active IP Right Grant
- 2008-07-28 ES ES16184094T patent/ES2805225T3/es active Active
- 2008-07-28 JP JP2010518431A patent/JP5401457B2/ja not_active Expired - Fee Related
- 2008-07-28 SG SG2013009832A patent/SG188128A1/en unknown
- 2008-07-28 KR KR1020107003133A patent/KR101722038B1/ko active IP Right Grant
- 2008-07-28 AU AU2008278593A patent/AU2008278593B2/en active Active
- 2008-07-28 US US12/669,705 patent/US8623811B2/en active Active
- 2008-07-28 BR BR122019000258-4A patent/BR122019000258B1/pt active IP Right Grant
- 2008-07-28 PL PL08826608T patent/PL2178549T3/pl unknown
- 2008-07-28 CN CN201210375756.5A patent/CN102872447B/zh active Active
- 2008-07-28 MX MX2010000916A patent/MX2010000916A/es active IP Right Grant
- 2008-07-28 CA CA2694046A patent/CA2694046C/en active Active
- 2008-07-28 DK DK16184094.7T patent/DK3120862T3/da active
- 2008-07-28 LT LTEP08826608.5T patent/LT2178549T/lt unknown
- 2008-07-28 SI SI200831732T patent/SI2178549T1/sl unknown
- 2008-07-28 HU HUE08826608A patent/HUE031136T2/en unknown
- 2008-07-28 CN CN200880100641.7A patent/CN101842107B/zh active Active
- 2008-07-28 PT PT88266085T patent/PT2178549T/pt unknown
- 2008-07-28 BR BRPI0813627-0A patent/BRPI0813627B1/pt active IP Right Grant
- 2008-07-28 ES ES08826608.5T patent/ES2609914T3/es active Active
- 2008-07-28 PT PT161840947T patent/PT3120862T/pt unknown
- 2008-07-28 KR KR1020177002763A patent/KR20170016031A/ko not_active Application Discontinuation
- 2008-07-28 WO PCT/US2008/071350 patent/WO2009015385A1/en active Application Filing
- 2008-07-28 NZ NZ582459A patent/NZ582459A/en unknown
- 2008-07-28 KR KR1020157019647A patent/KR101717275B1/ko active IP Right Grant
- 2008-07-28 KR KR1020187007958A patent/KR102088949B1/ko active IP Right Grant
- 2008-07-28 EP EP16184094.7A patent/EP3120862B1/en active Active
- 2008-07-28 DK DK08826608.5T patent/DK2178549T3/en active
-
2010
- 2010-01-06 IL IL203173A patent/IL203173A/en active IP Right Grant
- 2010-01-27 CR CR11239A patent/CR11239A/es not_active Application Discontinuation
- 2010-02-26 CO CO10023449A patent/CO6260098A2/es not_active Application Discontinuation
-
2012
- 2012-12-20 IL IL223784A patent/IL223784A/en active IP Right Grant
- 2012-12-20 IL IL223785A patent/IL223785A/en active IP Right Grant
-
2013
- 2013-06-28 HK HK13107613.7A patent/HK1180237A1/zh unknown
- 2013-10-28 JP JP2013222846A patent/JP5965884B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-04 JP JP2016132290A patent/JP2017002057A/ja active Pending
- 2016-12-14 HR HRP20161722TT patent/HRP20161722T1/hr unknown
- 2016-12-14 CY CY20161101296T patent/CY1118503T1/el unknown
-
2018
- 2018-08-17 JP JP2018153719A patent/JP6722241B2/ja active Active
-
2020
- 2020-06-19 JP JP2020105975A patent/JP2020169190A/ja active Pending
- 2020-07-27 CY CY20201100692T patent/CY1123176T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2694046C (en) | Cationic peptides and compositions thereof | |
ES2958621T3 (es) | Composiciones para el tratamiento tópico de infecciones microbianas | |
ES2846854T3 (es) | Composiciones antisépticas que comprenden iones de plata y mentol y usos de las mismas | |
US8513225B2 (en) | Composition and method for topical treatment of skin lesions | |
JP2019535767A (ja) | 抗菌ペプチド刺激用消毒組成物 | |
JP2015516943A (ja) | ポリペプチド及びその使用 | |
TWI430799B (zh) | 阿齊黴素於製造治療砂眼之醫藥品的用途及製造該醫藥品之方法 | |
ES2971823T3 (es) | Mejora de las acciones antibacterianas de un antibiótico depsipeptídico mediante cantidades sinérgicas de ácido bórico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2016 BY CPA GLOBAL Effective date: 20150724 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2017 BY CPA GLOBAL Effective date: 20160701 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2018 BY CPA GLOBAL Effective date: 20170713 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2019 BY CPA GLOBAL Effective date: 20180614 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2020 BY CPA GLOBAL Effective date: 20190704 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2021 BY THOMSON REUTERS Effective date: 20200721 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2022 BY THOMSON REUTERS Effective date: 20210604 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2023 BY THOMSON REUTERS Effective date: 20220603 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUL 2024 BY THOMSON REUTERS Effective date: 20230703 |